This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called dapirolizumab pegol for people with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body. The purpose of this study is to evaluate how well patients tolerate this treatment over an extended period.

Participants in this study will receive dapirolizumab pegol through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor participants for any side effects or adverse reactions that may occur during the treatment. The study will also assess whether the treatment can help prevent severe flare-ups of the disease, which are periods when symptoms become more intense.

The study will last for a total of 104 weeks, during which participants will have regular check-ups to track their progress and any changes in their condition. The goal is to ensure that the treatment is safe and effective for long-term use in managing Systemic Lupus Erythematosus. Participants who have completed a previous study involving a placebo may be eligible to join this extension study to continue receiving the treatment.